1-14 of 14
Caron A. Jacobson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A real-world comparison of commercial use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma

Andrew Looka, David A Qualls, Daniel Matthews, Robert A Redd, Christopher Sakellis, Caitlyn Duffy, Jamie Dela Cruz, Anna Saucier, Philippe Armand, Jennifer L. Crombie, David C. Fisher, Eric D. Jacobsen, Austin I Kim, Ann S LaCasce, Reid W Merryman, Erin M. Parry, Caron A. Jacobson
Journal: Blood Advances
Blood Adv bloodadvances.2024012992.
https://doi.org/10.1182/bloodadvances.2024012992
Published: 2024
Includes: Supplemental data
Journal Articles

Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

Clinical Trials & Observations
Armin Ghobadi, Javier Munoz, Jason R. Westin, Frederick L. Locke, David B. Miklos, Aaron P. Rapoport, Miguel-Angel Perales, Patrick M. Reagan, Joseph McGuirk, Caron A. Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O. Oluwole
Journal: Blood Advances
Blood Adv (2024) 8 (11): 2982–2990.
https://doi.org/10.1182/bloodadvances.2023011532
Published: 2024
Includes: Supplemental data
Journal Articles

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Clinical Trials & Observations
Inhye E. Ahn, Danielle M. Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A. Walker, Robert Black, Josie Montegaard, Alvaro Alencar, Leyla Shune, Mohammad Omaira, Caron A. Jacobson, Philippe Armand, Samuel Y. Ng, Jennifer Crombie, David C. Fisher, Ann S. LaCasce, Jon Arnason, Ephraim P. Hochberg, Ronald W. Takvorian, Jeremy S. Abramson, Jennifer R. Brown, Matthew S. Davids
Journal: Blood Advances
Blood Adv (2024) 8 (4): 832–841.
https://doi.org/10.1182/bloodadvances.2023011574
Published: 2024
Includes: Supplemental data
Journal Articles

Checkpoints: roadblocks or repairs for the CAR-T journey?

Clinical Trials & Observations
Jennifer L. Crombie, Caron A. Jacobson
Journal: Blood Advances
Blood Adv (2024) 8 (2): 468–469.
https://doi.org/10.1182/bloodadvances.2023012078
Published: 2024
Journal Articles

A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell–associated neurotoxicity syndrome

Clinical Trials & Observations
Caron A. Jacobson, Allison C. Rosenthal, Jon Arnason, Shirali Agarwal, Peixin Zhang, Wendy Wu, Vian Amber, Jean A. Yared
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6790–6799.
https://doi.org/10.1182/bloodadvances.2023009961
Published: 2023
Includes: Supplemental data
Journal Articles

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation

Reid W. Merryman, Robert A. Redd, Eleanor Taranto, Gulrayz Ahmed, Erin Jeter, Kristin M. McHugh, Jennifer R. Brown, Jennifer L. Crombie, Matthew S. Davids, David C. Fisher, Arnold S. Freedman, Eric Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Samuel Y. Ng, Oreofe O. Odejide, Erin M. Parry, Heather Jacene, Hyesun Park, Parastoo B. Dahi, Yago Nieto, Robin M. Joyce, Yi-Bin Chen, Margaret A. Shipp, Alex F. Herrera, Philippe Armand
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4748–4759.
https://doi.org/10.1182/bloodadvances.2022007706
Published: 2023
Includes: Supplemental data
Journal Articles

Comorbidities in DLBCL: too "Severe4" CAR-T therapy?

David Qualls, Caron A. Jacobson
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3469–3471.
https://doi.org/10.1182/bloodadvances.2023009834
Published: 2023
Journal Articles

Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma

Jessica S. Little, Muneerah M. Aleissa, Katherine Beluch, Isabel H. Gonzalez-Bocco, Francisco M. Marty, Jennifer Manne-Goehler, Sophia Koo, Sarah P. Hammond, Caron A. Jacobson
Journal: Blood Advances
Blood Adv (2022) 6 (16): 4821–4830.
https://doi.org/10.1182/bloodadvances.2022007474
Published: 2022
Journal Articles

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

Clinical Trials & Observations
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, Patrick M. Reagan, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, Michael Crump, John Kuruvilla, Eric Van Den Neste, Umar Farooq, Lynn Navale, Venita DePuy, Jenny J. Kim, Christian Gisselbrecht
Journal: Blood Advances
Blood Adv (2021) 5 (20): 4149–4155.
https://doi.org/10.1182/bloodadvances.2020003848
Published: 2021
Includes: Supplemental data
Journal Articles

Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma

Clinical Trials & Observations
Jennifer L. Crombie, Loretta J. Nastoupil, Robert Redd, Kevin Tang, Geoffrey Shouse, Alex F. Herrera, Victor A. Chow, Mazyar Shadman, Omar Castaneda Puglianini, Anna Saucier, Caron A. Jacobson, Philippe Armand, Gary Simmons
Journal: Blood Advances
Blood Adv (2021) 5 (18): 3563–3567.
https://doi.org/10.1182/bloodadvances.2021004880
Published: 2021
Journal Articles

C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas

Clinical Trials & Observations
Caron A. Jacobson, Marcela V. Maus
Journal: Blood Advances
Blood Adv (2020) 4 (22): 5858–5862.
https://doi.org/10.1182/bloodadvances.2020003391
Published: 2020
Journal Articles

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Clinical Trials & Observations
Frederick L. Locke, John M. Rossi, Sattva S. Neelapu, Caron A. Jacobson, David B. Miklos, Armin Ghobadi, Olalekan O. Oluwole, Patrick M. Reagan, Lazaros J. Lekakis, Yi Lin, Marika Sherman, Marc Better, William Y. Go, Jeffrey S. Wiezorek, Allen Xue, Adrian Bot
Journal: Blood Advances
Blood Adv (2020) 4 (19): 4898–4911.
https://doi.org/10.1182/bloodadvances.2020002394
Published: 2020
Includes: Supplemental data
Journal Articles

PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation

Matthew J. Frigault, Philippe Armand, Robert A. Redd, Erin Jeter, Reid W. Merryman, Kimberly C. Coleman, Alex F. Herrera, Parastoo Dahi, Yago Nieto, Ann S. LaCasce, David C. Fisher, Samuel Y. Ng, Oreife O. Odejide, Arnold S. Freedman, Austin I. Kim, Jennifer L. Crombie, Caron A. Jacobson, Eric D. Jacobsen, Jeffrey L. Wong, Jad Bsat, Sanjay S. Patel, Jerome Ritz, Scott J. Rodig, Margaret A. Shipp, Yi-Bin Chen, Robin M. Joyce
Journal: Blood Advances
Blood Adv (2020) 4 (1): 122–126.
https://doi.org/10.1182/bloodadvances.2019000784
Published: 2020
Includes: Supplemental data
Journal Articles

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia

Clinical Trials & Observations
Benjamin L. Lampson, Haesook T. Kim, Matthew S. Davids, Jeremy S. Abramson, Arnold S. Freedman, Caron A. Jacobson, Philippe A. Armand, Robin M. Joyce, Jon E. Arnason, Laura Z. Rassenti, Thomas J. Kipps, Joshua Fein, Stacey M. Fernandes, John R. Hanna, David C. Fisher, Jennifer R. Brown
Journal: Blood Advances
Blood Adv (2019) 3 (7): 1167–1174.
https://doi.org/10.1182/bloodadvances.2018030221
Published: 2019
Includes: Supplemental data